▶ DSIP · SUBTOPIC · SAFETY PROFILE
DSIP Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of DSIP.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of DSIP. Severity, frequency, and attribution depend on the source publication.
- Limited published safety data
- Reported well-tolerated in small Russian studies
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for DSIP.
- GABAergic medications (theoretical · unstudied)
- Benzodiazepines (theoretical additive sedation)
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for DSIP in the published record:
- Pregnancy/lactation (unstudied)
- Hypersensitivity
FDA REGULATORY STATUS
Not FDA-approved. Research-use only.
WADA REGULATORY STATUS
Not currently listed on the WADA Prohibited List (2026).
SAFETY Q+A FROM LITERATURE
▶ Is DSIP FDA-approved?
No. DSIP is research-use only. No FDA-approved indication.
▶ Is DSIP WADA-prohibited?
DSIP is not currently listed on the WADA Prohibited List as of 2026.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Schoenenberger GA, Monnier M. The isolation of a peptide which induces delta-sleep. Pflugers Arch 1977. PMID 195243. link
- Graf MV, Kastin AJ. Delta sleep-inducing peptide (DSIP): a review. Peptides 1986. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25